This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $624,001 to New York University (NYU) School of Medicine to develop a novel class of peptoid-based molecules called Multivalent Peptoid Conjugates (MPCs) that can antagonize the androgen receptor (AR) and potentially treat advanced, drug-resistant prostate cancer.
The key objectives are to: 1) Determine how MPCs modulate AR activity and gene expression in ways that block prostate cancer cell proliferation, 2) Assess whether MPCs can promote anti-tumor immunity and sensitize tumors to immune checkpoint blockade therapies, and 3) Conduct structural studies to understand the molecular mechanism of action of lead MPC compounds. NYU will collaborate with Emory University on this project through a $352,438 sub-award to support the development of these AR-targeting agents. The award period runs from August 1, 2024 to July 31, 2029.
Generated 2/25/25, 3:59 AM